p53 expression in low grade dysplasia in Barrett’s esophagus: correlation with interobserver agreement and disease progression

Skacel, Marek; Petras, Robert E.; Rybicki, Lisa A.; Gramlich, Terry L.; Richter, Joel E.; Falk, Gary W.; Goldblum, John R.
October 2002
American Journal of Gastroenterology;Oct2002, Vol. 97 Issue 10, p2508
Academic Journal
OBJECTIVES:The frequency of progression from low grade dysplasia (LGD) to high grade dysplasia/carcinoma (HGD/CA) in Barrett’s esophagus (BE) varies among studies. Current assessment is made more difficult because of pathologists’ interobserver variability in diagnosing LGD. We recently conducted an interobserver study on LGD and reported a positive correlation between the extent of agreement among GI pathologists and progression of LGD. In the current study, we analyzed the immunohistochemical staining for p53 in patients diagnosed with LGD with known clinical outcome and interobserver agreement data.METHODS:Fixed, paraffin-embedded endoscopic biopsy specimens from 16 patients diagnosed with LGD in BE were immunostained for p53 (DO-7, Dako, Carpinteria, CA). Hematoxylin and eosin-stained and immunostained sections were examined in tandem to determine whether the LGD areas in question stained for p53. The p53 immunoreactivity was correlated with clinical progression and with the interobserver agreement among three GI pathologists.RESULTS:The overall mean follow-up was 23 months (range 2–84 months). LGD areas in seven of eight patients (88%) who progressed to HGD/CA stained positively for p53 compared to only two of eight nonprogressors (25%). A correlation with clinical progression was seen for p53 positivity (p = 0.017; log-rank test), and for either p53 positivity or complete agreement among three GI pathologists on LGD diagnosis (p = 0.014; log-rank test). The p53 staining demonstrated 88% sensitivity and 75% specificity for progression of LGD to HGD/CA. Adding complete interobserver agreement on LGD among three experienced GI pathologists to p53 positivity resulted in improved sensitivity with no change in specificity (100% and 75%, respectively).CONCLUSIONS:In conjunction with histological evaluation by GI pathologists for a diagnosis of LGD, immunohistochemical staining for p53 can be used as an adjunctive test, as it correlated with progression to HGD/CA in this series.


Related Articles

  • p53 immunoprofiling of potentially malignant oral disorders: A case series analysis. Reddy, V. M.; Kamath, A.; Radhakrishnan, R. A. // Indian Journal of Cancer;Jan-Mar2012, Vol. 49 Issue 1, p27 

    CONTEXT: p53 tumor suppressor gene which is a frequent target for mutations in a high percentage of oral cancer is regarded as an early event in carcinogenesis. AIM: The role of p53 was assessed in potentially malignant oral disorders (PMOD) to ascertain its prognostic significance. SETTINGS AND...

  • Hallazgos histopatológicos y expresión de p53 y Ki67 en queilitis actínica. Mercadillo-Pérez, Patricia; Moreno-López, Luis Miguel // Revista Medica del Hospital General de Mexico;abr-jun2012, Vol. 75 Issue 2, p90 

    Introduction: Actinic cheilitis is the most common premalignant lesion of the lip, and it is frequently located on the lower lip. In premalignant and malignant oral lesions, p53 mutations have been reported in a very high frequency, and it has been shown that the Ki67 expression has a role in...

  • P53 Overexpression and Steroid Hormone Receptor Status in Endometrial Carcinoma. Fernando, Sujatha S.E. // International Journal of Surgical Pathology;Jul2000, Vol. 8 Issue 3, p213 

    Examines the overexpression of p53 protein in primary endometrial carcinomas. Association between nuclear p53 protein immunoreactivity and pathological features; Analysis of the immunohistochemical expression of estrogen receptors, progesterone receptors and pS2 protein; Correlation between...

  • Response of Ewing tumor cells to forced and activated p53 expression. Kovar, Heinrich; Pospisilova, Sarka; Jug, Gunhild; Printz, Dieter; Gadner, Helmut // Oncogene;5/22/2003, Vol. 22 Issue 21, p3193 

    The EWS-FLI1 transcription factor is consistently expressed in 85% of Ewing tumors (EFT). In heterologous cells, EWS-FLI1 induces p53-dependent cell cycle arrest or apoptosis. It has been speculated that the p53 tumor suppressor pathway may be generally compromised in EFT despite only rare p53...

  • Synergistic and opposing regulation of the stress-responsive gene IEX-1 by p53, c-Myc, and multiple NF-κB/rel complexes. Huang, Yan-Hong; Wu, Jim Yujin; Zhang, Yujin; Wu, Mei X. // Oncogene;10/3/2002, Vol. 21 Issue 44, p6819 

    Provides information on a study that examined how transcription factors Nf-κB/rel proteins, p53 and c-Myc coordinarily control immediate early response gene X-1 expression. Results and discussion; Materials and methods used.

  • Nucleophosmin regulates the stability and transcriptional activity of p53. Colombo, Emanuela; Marine, Jean-Christophe; Danovi, Davide; Falini, Brunangelo; Pelicci, Pier Giuseppe // Nature Cell Biology;Jul2002, Vol. 4 Issue 7, p529 

    Nucleophosmin (NPM) is a ubiquitously expressed nucleolar phosphoprotein that continuously shuttles between the nucleus and cytoplasm. It has been proposed to function in ribosomal protein assembly and transport, and also as a molecular chaperone that prevents proteins from aggregating in the...

  • Overexpression of p53 tumor suppressor gene in pterygia. Weinstein, O.; Rosenthal, G.; Zirkin, H.; Monos, T.; Lifshitz, T.; Argov, S. // Eye;Sep2002, Vol. 16 Issue 5, p619 

    Assesses p53 gene expression in pterygia with and without recurrence. Identification of prognostic factor for recurrence; Cell proliferation; Gene localization; Prevalence of p53 abnormal expression.

  • Development and validation of sensitive assays to quantitate gene expression after p53 gene therapy and paclitaxel chemotherapy using in vivo dosing in tumor xenograft models. Wen, Shu Fen; Xie, Lei; McDonald, Matthew; DiGiacomo, Ruth; Chang, Alice; Gurnani, Maya; Shi, Bin; Liu, Suxing; Indelicato, Stephen R; Hutchins, Beth; Nielsen, Loretta L // Cancer Gene Therapy;Nov2000, Vol. 7 Issue 11, p1469 

    SCH58500 (ACN53) is a replication-deficient, type 5 adenovirus (Ad) expressing human wild-type p53 tumor suppressor. It is currently undergoing clinical trials as a cancer therapeutic. Many SCH58500 clinical trials incorporate an arm comparing traditional chemotherapy against chemotherapy...

  • MAYO CLINIC: PROCEEDINGS. Genden, Eric M.; Aguirre-Ghiso, Julio A. // Mayo Clinic Proceedings;Mar2012, Vol. 87 Issue 3, p211 

    An introduction to the journal is presented in which the editor discusses various articles within the issue on topics including oropharyngeal cancer, expression of p53 gene pathway, and genetic profiling of oropharyngealsquamouscell carcinoma (OPSCC) tumors.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics